Cytokinetics' MYQORZO Receives FDA Approval for Enhanced Label Data on Obstructive Hypertrophic Cardiomyopathy Treatment
Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for MYQORZO® (aficamten). This approval updates the drug's U.S. prescribing information to include data from the MAPLE-HCM Phase 3 trial. The trial compared the efficacy of MYQORZO to metoprolol, a standard-of-care beta-blocker, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO demonstrated superior improvements in exercise capacity, symptoms, and cardiac biomarkers compared to metoprolol. This makes MYQORZO the only cardiac myosin inhibitor with comparative effectiveness data against a beta-blocker in its U.S. label. The drug, initially approved in December 2025 based on the SEQUOIA-HCM trial, is also approved in China, the European Union, the United Kingdom, and Canada. MYQORZO carries a Boxed Warning due to the risk of heart failure and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program, r...